Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.

Xue W, Jin X, Ning L, Wang M, Liu H, Yao X.

J Chem Inf Model. 2013 Jan 28;53(1):210-22. doi: 10.1021/ci300541c. Epub 2012 Dec 20.

PMID:
23231029
2.

Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study.

Xue W, Qi J, Yang Y, Jin X, Liu H, Yao X.

Mol Biosyst. 2012 Aug;8(8):2135-44. doi: 10.1039/c2mb25114k. Epub 2012 May 30.

PMID:
22648037
3.

Impact of resistance mutations on inhibitor binding to HIV-1 integrase.

Chen Q, Buolamwini JK, Smith JC, Li A, Xu Q, Cheng X, Wei D.

J Chem Inf Model. 2013 Dec 23;53(12):3297-307. doi: 10.1021/ci400537n. Epub 2013 Nov 21.

PMID:
24205814
5.

2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance.

Desimmie BA, Demeulemeester J, Suchaud V, Taltynov O, Billamboz M, Lion C, Bailly F, Strelkov SV, Debyser Z, Cotelle P, Christ F.

ACS Chem Biol. 2013;8(6):1187-94. doi: 10.1021/cb4000426. Epub 2013 Apr 2.

PMID:
23517458
6.

Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.

Johnson BC, Métifiot M, Pommier Y, Hughes SH.

Antimicrob Agents Chemother. 2012 Jan;56(1):411-9. doi: 10.1128/AAC.05292-11. Epub 2011 Oct 28.

7.

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA.

J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.

8.

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

DeAnda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, Kawasuji T, Underwood MR.

PLoS One. 2013 Oct 16;8(10):e77448. doi: 10.1371/journal.pone.0077448. eCollection 2013.

9.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.

J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.

10.

Resistance to HIV-1 integrase inhibitors: A structural perspective.

Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L.

Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50. doi: 10.1016/j.drup.2010.05.001. Epub 2010 Jun 8. Review.

PMID:
20570551
11.

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF.

Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12.

PMID:
21669228
12.

Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.

Dewdney TG, Wang Y, Kovari IA, Reiter SJ, Kovari LC.

J Struct Biol. 2013 Nov;184(2):245-50. doi: 10.1016/j.jsb.2013.07.008. Epub 2013 Jul 25.

PMID:
23891838
13.
14.

Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).

Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P.

Mol Pharmacol. 2011 Oct;80(4):565-72. doi: 10.1124/mol.111.073189. Epub 2011 Jun 30.

15.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

16.

Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase.

Chen Q, Cheng X, Wei D, Xu Q.

Interdiscip Sci. 2015 Mar;7(1):36-42. doi: 10.1007/s12539-014-0235-8. Epub 2014 Nov 6.

PMID:
25519157
17.

Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization.

Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, Butler S, Smets W, Chaltin P, Westby M, Debyser Z, Pickford C.

Antimicrob Agents Chemother. 2012 Aug;56(8):4365-74. doi: 10.1128/AAC.00717-12. Epub 2012 Jun 4.

18.

Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.

Loizidou EZ, Zeinalipour-Yazdi CD, Christofides T, Kostrikis LG.

Bioorg Med Chem. 2009 Jul 1;17(13):4806-18. doi: 10.1016/j.bmc.2009.04.058. Epub 2009 May 3.

PMID:
19450984
19.

HIV-1 Group O Resistance Against Integrase Inhibitors.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):9-15. doi: 10.1097/QAI.0000000000000698.

PMID:
26017662
20.

Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via molecular docking and comparative molecular dynamics simulation methods.

Hu JP, He HQ, Tang DY, Sun GF, Zhang YQ, Fan J, Chang S.

J Biomol Struct Dyn. 2013;31(7):734-47. doi: 10.1080/07391102.2012.709458. Epub 2012 Aug 22.

PMID:
22913375

Supplemental Content

Support Center